研究実績  |  RESULTS ACHIEVEMENT

英文論文

    2024
  • Takenaka Y, Kakinuma Y, Ikeda M, Inoue I. Shared Mechanisms in Pparγ1sv and Pparγ2 Expression in 3T3-L1 Cells: Studies on Epigenetic and Positive Feedback Regulation of Pparγ during Adipogenesis. PPAR Research 2024 (in press).

  • 2024
  • Ito D, Inoue I, Yanagisawa S, Inoue K, Saito D, Sumita T, Uchida Y, Inukai K, Shimada A. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5-year observational follow-up of a randomized, 24-week, active-controlled trial. J Diabetes Investig. 2024. (In press) 

  • 2024
  • Yanagisawa S, Oikawa Y, Endo M, Inoue K, Nakajima R, Yasuda S, Sato M, Iwata N, Fujisawa H, Suzuki A, Sugimura Y, Isshiki M, Shimada A. A pregnant woman with excess vasopressinase-induced diabetes insipidus complicated by central diabetes insipidus like lymphocytic infundibulo-neurohypophysitis‍: a case report. Case Rep Endocrinol. 2024 Apr 13;2024:8687054.

  • 2024
  • Kawasaki E, Awata T, Ikegami H, Imagawa A, Oikawa Y, Osawa H, Katsuki T, Kanatsuna N, Kawamura R, Kozawa J, Kodani N, Kobayashi T, Shimada A, Shimoda M, Takahashi K, Chujo D, Tsujimoto T, Tsuchiya K, Terakawa A, Terasaki J, Nagasawa K, Noso S, Fukui T, Horie I, Yasuda K, Yasuda H, Yanai H, Hanafusa T, Kajio H; Japanese Type 1 Diabetes Database Study (TIDE-J). Prediction of future insulin-deficiency in glutamic acid decarboxylase autoantibody enzyme-linked immunosorbent assay-positive patients with slowly-progressive type 1 diabetes. J Diabetes Investig. 2024 Mar 7 (In press).

  • 2024
  • Mizutani G, Isshiki M, Shimizu E, Saito D, Shimada A. Pheochromocytoma With High Adrenocorticotropic Hormone Production Capacity Without Pigmentation and Cushingoid Symptoms: A Case Report With a Literature Review. Cureus. 2024 Feb 1;16(2):e53358.

  • 2024
  • Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, Kajio H, Kozawa J, Takahashi K, Chujo D, Noso S, Fukui T, Miura J, Yasuda K, Yasuda H, Imagawa A, Ikegami H. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version).  J Diabetes Investig. 2024 Feb;15(2):254-257.

  • 2024
  • Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, Kajio H, Kozawa J, Takahashi K, Chujo D, Noso S, Fukui T, Miura J, Yasuda K, Yasuda H, Imagawa A, Ikegami H. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version). Diabetol Int. 2024 Jan 8;15(1):1-4. 

  • 2024
  • Yamanouchi Y, Senbonmatsu T, Yamaguchi T, Inoue I, Goto S, Soma T, Maruyama Y, Adachi M, Shinozuka N, Muramatsu T. Medical Record Survey after Comprehensive Health Checkup Referral and Its Contribution to the Early Detection of Cancer. J Pers Med. 2024, 14:59. 

  • 2023
  • Kawai S, Yamakage H, Kotani K, Noda M, Satoh-Asahara N, Hashimoto K. Differences in metabolic characteristics between Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUO) in weight reduction therapy. Endocr J. 2023 Dec 28;70(12):1175-1186. 

  • 2023
  • Nishimura R, Shimada A, Abiru N, Matsuhisa M, Takahashi Y, Ikegami H. Association between glycemic control and patient-reported outcomes in adults with type 1 diabetes in Japan: the SAGE study subanalysis. Diabetol Int. 2023 Nov 22;15(2):212-222. 

  • 2023
  • Toyoda M, Murata T, Hirota Y, Hosoda K, Kato K, Kouyama K, Kouyama R, Kuroda A, Matoba Y, Matsuhisa M, Meguro S, Miura J, Nishimura K, Shimada A, Suzuki S, Tone A, Sakane N; ISCHIA Study Group. Possible Relationship between the Deteriorated Accuracy of Intermittent-Scanning Continuous Glucose Monitoring Device and the Contact Dermatitis: Post-hoc analysis of the ISCHIA Study. Tokai J Exp Clin Med. 2023 Sep 20;48(3):83-90. 

  • 2023
  • Takenaka Y, Inoue I, Hirasaki M, Ikeda M, Kakinuma Y. Temporal inhibition of the electron transport chain attenuates stress-induced cellular senescence by prolonged disturbance of proteostasis in human fibroblasts. FEBS J. 2023 Aug;290(15):3843-3857.

  • 2023
  • Horii T, Oikawa Y, Shimada A, Mihara K. Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan. J Diabetes Investig. 2023 Nov;14(11):1262-1267.

  • 2023
  • Bouchi R, Noda M, Hayashino Y, Goto A, Yamazaki K, Suzuki H, Furukawa TA, Izumi K, Kobayashi M; J-DOIT2 Study Group. Behavioral change stage might moderate the impact of multifaceted interventions on non-attendance from medical care among patients with type 2 diabetes: The Japan Diabetes Outcome Intervention Trial-2 Large-Scale Trial 007 (J-DOIT2-LT007). J Diabetes Investig. 2023 Jul;14(7):907-916. 

  • 2023
  • Tamura Y, Kaga H, Abe Y, Yoshii H, Seino H, Hiyoshi T, Kuribayashi N, Inoue I, Watada H. Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). Nutrients. 2023 Jun 24;15(13):2866.

  • 2023
  • Fukui T, Kobayashi T, Jimbo E, Aida K, Shimada A, Oikawa Y, Mori Y, Fujii T, Koyama R, Kobayashi K, Takeshita A, Yagihashi S. Bi-glandular and persistent enterovirus infection and distinct changes of the pancreas in slowly progressive type 1 diabetes mellitus. Sci Rep. 2023 Apr 28;13(1):6977.

  • 2023
  • Yasuda S, Suzuki S, Yanagisawa S, Morita H, Haisa A, Satomura A, Nakajima R, Oikawa Y, Inoue I, Shimada A. HLA typing of patients who developed subacute thyroiditis and Graves’ disease after SARS-CoV-2 vaccination: a case report. BMC Endocr Disord. 2023 Mar 7;23(1):54. 

  • 2023
  • Kawasaki E, Shimada A, Imagawa A, Abiru N, Awata T, Oikawa Y, Osawa H, Kawabata Y, Kozawa J, Kobayashi T, Takahashi K, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kajio H, Hanafusa T, Ikegami H; Committee of type 1 diabetes, Japan Diabetes Society. Bivalent GAD autoantibody ELISA Improves clinical utility and risk prediction for adult autoimmune diabetes. J Diabetes Investig. 2023 Apr;14(4):570-581.

  • 2023
  • Yamanouchi Y, Inoue I, Goto S, Maruyama Y. Obesity, Atherosclerotic Risk Factors, and Metabolic Syndrome in Vascular Aging and Treatment in the Elderly. Health Evaluation and Promotion. 2023;50(4):403-411.

  • 2023
  • ISCHIA Study Group. Prevention of hypoglycemia by intermittent-scanning continuous glucose monitoring device combined with structured education in patients with type 1 diabetes mellitus: A randomized, crossover trial.  Diabetes Res Clin Pract. 2023 Jan;195:110147.

  • 2023
  • Kawasaki E, Shimada A, Imagawa A, Abiru N, Awata T, Oikawa Y, Osawa H, Kawabata Y, Kozawa J, Kobayashi T, Takahashi K, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kajio H, Hanafusa T, Ikegami H; Committee of type 1 diabetes, Japan Diabetes Society. Comparing the clinical significance and antigen specificity of insulinoma-associated antigen-2 autoantibodies between radioimmunoassay and enzyme-linked immunosorbent assay in Japanese patients with type 1 diabetes. J Diabetes Investig. 2023 Jan;14(1):58-66.

  • 2022
  • Mizutani G*, Horii T*, Oikawa Y, Atsuda K, Shimada A. Real-world risk of lower-limb amputation associated with sodium–glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan. J Diabetes Investig. 2022 Dec;13(12):2000-2009. * These authors contributed equally to this work.

  • 2022
  • Shimada A, Toda K, Inoue I, Yamada T, Oikawa Y. Combination of anti-CD25 antibody and poly I:C treatment in pregnant NOD mice may be used as “pregnancy-related” type 1 diabetes model. J Diabetes Investig. 2022 Sep;13(9):1489-1495. 

  • 2022
  • Satomura A, Oikawa Y, Sato H, Takagi S, Yamashita T, Shimada A. A Patient with Ketosis-prone Type 2 Diabetes Showing Nearly Normalized Glucose Tolerance after Recovery from Severe Diabetic Ketoacidosis. Diabetol Int. 2022 Jul 28;14(1):109-113.

  • 2022
  • Yanagisawa S, Oikawa Y, Takagi S, Horikoshi Y, Satomura A, Imai K, Sakai J, Ishibashi N, Tarumoto N, Iida S, Nakayama H, Haga Y, Maesaki S, Shimada A. HbA1c level may be a risk factor for oxygen therapy requirement in patients with coronavirus disease 2019. J Diabetes Investig. 2022 May;13(5):909-917. 

  • 2022
  • Yamanouchi Y, Maeda K, Shinoda Y, Majima M, Lee J, Inoue I, Maruyama Y, Kurabayashi H. Can outpatient rehabilitation be continued during the COVID-19 pandemic? A report from a Japanese regional medical university hospital. Arch Rehabil Res Clin Transl. 2022 May 2:100199. 

  • 2022
  • Tanaka M, Yamakage H, Muranaka K, Yamada T, Araki R, Ogo A, Matoba Y, Watanabe T, Saito M, Kurita S, Yonezawa K, Tanaka T, Suzuki M, Sawamura M, Matsumoto M, Nishimura M, Kusakabe T, Wada H, Hasegawa K, Kotani K, Noda M, Satoh-Asahara N. Higher Serum Soluble TREM2 as a Potential Indicative Biomarker for Cognitive Impairment in Inadequately Controlled Type 2 Diabetes Without Obesity: The DOR-KyotoJ-1. Front Endocrinol (Lausanne). 2022 May 3;13:880148. 

  • 2022
  • Satomura A, Oikawa Y, Haisa A, Suzuki S, Nakanishi S, Katsuki T, Shimada A. Clinical significance of insulin peptide-specific interferon-γ-related immune responses in ketosis-prone type 2 diabetes. J Clin Endocrinol Metab. 2022 Apr 19;107(5):e2124-e2132. 

  • 2022
  • Oikawa Y, Hashimoto K, Hara K, Morimoto J, Namai K, Tanaka A, Tanaka S, Shimada A. Current clinical state of type 1 diabetes in Saitama prefecture. Diabetol Int. 2022 April 4;13(2):436-446. 

  • 2022
  • Takenaka Y, Inoue I, Nakano T, Ikeda M, Kakinuma Y. Prolonged disturbance of proteostasis induces cellular senescence via temporal mitochondrial dysfunction and subsequent mitochondrial accumulation in human fibroblasts. FEBS J. 2022 Mar;289(6):1650-1667.

  • 2022
  • Takao T, Yanagisawa H, Suka M, Yoshida Y, Onishi Y, Tahara T, Kikuchi T, Kushiyama A, Anai M, Takahashi K, Wakabayashi Sugawa S, Yamazaki H, Kawazu S, Iwamoto Y, Noda M, Kasuga M. Synergistic association of the copper/zinc ratio under inflammatory conditions with diabetic kidney disease in patients with type 2 diabetes: The Asahi Diabetes Complications Study. J Diabetes Investig. 2022 Feb;13(2):299-307. 

ACCESSご案内

埼玉医科大学

埼玉医科大学病院

〒350-0495 埼玉県入間郡毛呂山町毛呂本郷38
TEL: 049-276-1111(代)
FAX: 049-294-9752

お車をご利用される方
鶴ヶ島インターから約10km(約20~30分)
詳しくはこちら

電車・バスをご利用される方
池袋駅より東毛呂駅まで約1時間
東毛呂駅からバス(約5分)もしくは徒歩(約20分)
詳しくはこちら

本フォームは医療従事者専用となっております。ご病状やお薬、検査、予約など診療に関する患者さんからのご相談は、法律上、一切お受けすることができません。ご理解のほどよろしくお願いいたします。